Evaluation of the pulmonary and systemic immunogenicity of Fluidosomes, a fluid liposomal-tobramycin formulation for the treatment of chronic infections in lungs
S. Sachetelli et al., Evaluation of the pulmonary and systemic immunogenicity of Fluidosomes, a fluid liposomal-tobramycin formulation for the treatment of chronic infections in lungs, BBA-GEN SUB, 1428(2-3), 1999, pp. 334-340
In previous studies, we have developed a fluid bactericidal liposomal formu
lation containing tobramycin, called Fluidosomes, which has been shown to b
e highly bactericidal both in in vitro and in in vivo studies against Pseud
omonas aeruginosa and other related and unrelated bacteria. One foreseeable
application of these Fluidosomes is the treatment of chronic pulmonary inf
ections in cystic fibrosis patients colonized with P. aeruginosa and other
related bacteria. Considering the capacity of some liposomal preparations t
o play an adjuvant role in vaccines, the non-immunogenicity of Fluidosomes
has to be demonstrated. The systemic and local immunogenicity of Fluidosome
s were assessed by effectuating repeated intraperitoneal (i.p.) and intratr
acheal (i.t.) immunizations in BALB/c mouse. No significant mucosal and ser
um immune responses against Fluidosomes and/or tobramycin were detected as
compared with preimmune sera. These data suggest that Fluidosomes could be
administered repeatedly without adverse immune responses to control chronic
pulmonary infections in cystic fibrosis. (C) 1999 Elsevier Science B.V. Al
l rights reserved.